Inclusion Criteria:

- Patients who had mCRC and metastases confined to the liver

- Patients in whom downsizing regimens are recommended

- Patients in whom downsizing treatment included cetuximab

- Patients referred to Hepatobiliary Multi Disciplinary Team (HPB MDT) between
01.01.2010-31.03.2011

Exclusion Criteria:

- Patients who are considered to have immediately resectable liver metastases as
determined by the HPB MDT

- Patients who are considered to have never resectable liver metastases as determined
by the HPB MDT

- Patients who were aged less than 18 at date of initiation of cetuximab

- Patients who are enrolled in a clinical trial during the data collection period

- Patients who are receiving private healthcare for the treatment of mCRC

- According to Summary of Product Characteristics (SmPC)